Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been...
Servier Group’s Pancreatic Cancer Therapy Onivyde Launches in Major Chinese Cities
France-based Servier has announced the first prescriptions for its pancreatic cancer therapy, Onivyde (irinotecan), in...
Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first...
CDE Releases 73rd Batch of Chemical Generic Reference Preparations with Updates
The Center for Drug Evaluation (CDE) has released the 73rd batch of chemical generic reference...
Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first...
Watchmaker Genomics and Exact Sciences Corporation Ink Deal to Advance TAPS Technology
US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation...
XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with...
Takeda Secures Exclusive Rights to ImmunoGen’s Elahere in Japan Through New Agreement
Japanese pharmaceutical company Takeda (TYO: 4502) has entered into an exclusive collaboration and license agreement...
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...
Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the...
Pfizer and BioNTech Receive Positive CHMP Opinion for Comirnaty Vaccine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been...
Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots
Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200...
AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...
Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies
Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)...
Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy
Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...
Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...
CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...
Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...